Autologous versus Non-autologous Exosomes: Immunological, Safety, and Regulatory Considerations in Regenerative Medicine

Authors:
  • IMIvanny Marchant
    Ivanny Marchant
  • BRBelén Rodríguez
    Belén Rodríguez
  • VPValentina Pozo
    Valentina Pozo
  • LPLeopoldo Parada
    Leopoldo Parada
  • CSCarla Salvo
    Carla Salvo

Abstract
Small extracellular vesicles (sEVs), commonly referred to as exosomes, have emerged as novel therapeutic tools in regenerative and esthetic medicine. A critical decision in their clinical application is the choice between autologous and non-autologous products, as this distinction directly impacts safety, immunocompatibility, efficacy, and regulatory compliance. This review analyzes the immunological profile and biological risks associated with exosomes’ clinical use according to their cellular origin, addressing persistence, pathogen transmission, delivery routes, and regulatory classification. Furthermore, we highlight the strategic role of blood centers and biobanks in producing high-safety allogeneic sEVs, especially those derived from human platelets and mesenchymal stromal cells expanded in xenofree conditions. While autologous exosomes offer maximal immunological safety, standardized allogeneic strategies free from animal-derived components represent a scalable and regulatory-compatible alternative for modern regenerative therapies. Keywords: Exosomes, Regenerative Medicine, Autologous Exosomes, Non-autologous Exosomes